Cello Health PLC Total Voting Rights (6659B)

TIDMCLL

RNS Number : 6659B

Cello Health PLC

10 June 2019

10 June 2019

Cello Health plc

Total Voting Rights

As at 10 June 2019, Cello's issued share capital comprises 105,565,309 ordinary shares of 10 pence each ("Ordinary Shares"), of which 453,000 Ordinary Shares are held in treasury. The total number of current voting rights in the Company is therefore 105,112,309 Ordinary Shares.

The above figure (105,112,309 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 
 Cello Health plc               020 7812 8460 
 Mark Scott, Chief Executive 
 Mark Bentley, Group Finance 
  Director 
 Cenkos Securities plc          020 7397 8900 
 Mark Connelly 
 Harry Hargreaves 
 
 Buchanan 
  Mark Court                    020 7466 5000 
 Jamie Hooper 
 Sophie Wills 
 
 

About Cello Health plc

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

TVRVBLBFKQFXBBV

(END) Dow Jones Newswires

June 10, 2019 04:41 ET (08:41 GMT)